Jason Kolbert, Sr. Research Analyst at the Maxim Group, who started DNDN with a sell on DNDN, now has a buy with a 10.00 target.
They will do around 300 to 400 mil in revs in USA alone, 50% in margins you'll get 200 mil in free cash flow. Three to five times suggest a take out value of 1 to 1.5 billion. A company THAT ALREADY HAS the infrastructure for prostate cancer like Astellas Pharma, Inc. (ALPMY) or JNJ, would dovetail in existing products.
All posts are In my opinion, and are not meant to harm or defame anyone, please do your own DD. Please click on my Favorite Links, Journey to the Edge of the Universe & tell me what you think.